Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Viswanath, Ambily Nath Indu | - |
dc.contributor.author | Pae, Ae Nim | - |
dc.date.accessioned | 2024-01-20T11:34:38Z | - |
dc.date.available | 2024-01-20T11:34:38Z | - |
dc.date.created | 2021-09-04 | - |
dc.date.issued | 2013-08-22 | - |
dc.identifier.issn | 0022-2623 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/127761 | - |
dc.description.abstract | Talapatra et al. elucidated the molecular basis of resistance by characterizing the binding interactions between Eg5 and the allosteric inhibitor SB743921. The investigation, employing biochemical, biophysical, and structural analyses, made path-breaking revelations in Eg5 studies and discussed a novel phenomenon "resistance by allostery", which could have far-reaching consequences from a rational drug design perspective. | - |
dc.language | English | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.subject | PHASE-II | - |
dc.subject | INHIBITOR | - |
dc.subject | PHARMACOKINETICS | - |
dc.subject | CARCINOMA | - |
dc.subject | ISPINESIB | - |
dc.subject | SB-715992 | - |
dc.subject | RECURRENT | - |
dc.subject | EG5 | - |
dc.title | Resistance by Allostery: A Novel Perspective for Eg5-Targeted Drug Design | - |
dc.type | Article | - |
dc.identifier.doi | 10.1021/jm401071u | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | JOURNAL OF MEDICINAL CHEMISTRY, v.56, no.16, pp.6314 - 6316 | - |
dc.citation.title | JOURNAL OF MEDICINAL CHEMISTRY | - |
dc.citation.volume | 56 | - |
dc.citation.number | 16 | - |
dc.citation.startPage | 6314 | - |
dc.citation.endPage | 6316 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000323593400003 | - |
dc.identifier.scopusid | 2-s2.0-84883163795 | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | ISPINESIB | - |
dc.subject.keywordPlus | SB-715992 | - |
dc.subject.keywordPlus | RECURRENT | - |
dc.subject.keywordPlus | EG5 | - |
dc.subject.keywordAuthor | Eg5 | - |
dc.subject.keywordAuthor | Kinesin Spindle Protein | - |
dc.subject.keywordAuthor | Allostery | - |
dc.subject.keywordAuthor | anticancer | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.